Hypertension Clinical Trial
Official title:
Peds I (Pediatric Eplerenone Development Study I): A Randomized, Double-Blind, Placebo Withdrawal, Parallel Group, Dose-Response Study To Evaluate The Efficacy And Safety Of Eplerenone In The Treatment Of Hypertension In Children
Verified date | December 2020 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To evaluate the efficacy, safety, and toleration of eplerenone in the treatment of children aged 6 to 16 years with high blood pressure. The study will last approximately 10 weeks and about 320 patients will participate.
Status | Completed |
Enrollment | 320 |
Est. completion date | January 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 16 Years |
Eligibility | Inclusion Criteria: - 6-16 years old male and female - Systolic blood pressure greater than or equal to the 95th percentile for age, gender, and height, measured on at least 3 separate occasions Exclusion Criteria: - K/DOQI classification of stages of chronic kidney disease equal to or greater than 3 - Serum or whole blood potassium > 5.5 mEq/L |
Country | Name | City | State |
---|---|---|---|
Dominican Republic | Pfizer Investigational Site | Santo Domingo | DN |
India | Pfizer Investigational Site | Bangalore | Karnataka |
India | Pfizer Investigational Site | Chennai | Tamil Nadu |
Russian Federation | Pfizer Investigational Site | Moscow | |
Russian Federation | Pfizer Investigational Site | Smolensk | |
Russian Federation | Pfizer Investigational Site | St. Petersburg | |
South Africa | Pfizer Investigational Site | Cape Town | |
South Africa | Pfizer Investigational Site | Capital Park | Gauteng |
South Africa | Pfizer Investigational Site | Johannesburg | Gauteng |
South Africa | Pfizer Investigational Site | Parow | Western Cape |
South Africa | Pfizer Investigational Site | Polokwane | Lipompo Province |
South Africa | Pfizer Investigational Site | Pretoria | Gauteng |
South Africa | Pfizer Investigational Site | Soweto | Gauteng |
United States | Pfizer Investigational Site | Ann Arbor | Michigan |
United States | Pfizer Investigational Site | Augusta | Georgia |
United States | Pfizer Investigational Site | Beaumont | Texas |
United States | Pfizer Investigational Site | Beverly Hills | California |
United States | Pfizer Investigational Site | Boston | Massachusetts |
United States | Pfizer Investigational Site | Carrboro | North Carolina |
United States | Pfizer Investigational Site | Chapel Hill | North Carolina |
United States | Pfizer Investigational Site | Cleveland | Ohio |
United States | Pfizer Investigational Site | Columbus | Ohio |
United States | Pfizer Investigational Site | Houston | Texas |
United States | Pfizer Investigational Site | Inglewood | California |
United States | Pfizer Investigational Site | Jackson | Mississippi |
United States | Pfizer Investigational Site | Jacksonville | Florida |
United States | Pfizer Investigational Site | Katy | Texas |
United States | Pfizer Investigational Site | Little Rock | Arkansas |
United States | Pfizer Investigational Site | Livingston | New Jersey |
United States | Pfizer Investigational Site | Los Angeles | California |
United States | Pfizer Investigational Site | Louisville | Kentucky |
United States | Pfizer Investigational Site | Memphis | Tennessee |
United States | Pfizer Investigational Site | Miami | Florida |
United States | Pfizer Investigational Site | Park Ridge | Illinois |
United States | Pfizer Investigational Site | Philadelphia | Pennsylvania |
United States | Pfizer Investigational Site | Pittsboro | North Carolina |
United States | Pfizer Investigational Site | Portland | Oregon |
United States | Pfizer Investigational Site | Shreveport | Louisiana |
United States | Pfizer Investigational Site | Tulsa | Oklahoma |
United States | Pfizer Investigational Site | Tupelo | Mississippi |
United States | Pfizer Investigational Site | Youngstown | Ohio |
Lead Sponsor | Collaborator |
---|---|
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
United States, Dominican Republic, India, Russian Federation, South Africa,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy of eplerenone in children | |||
Secondary | Safety and tolerability of eplerenone in hypertensive children |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |